AI discovery
Clinical-stage · Cambridge, MA
Engineering biology
at programmable scale.
Helix Bio combines AI-guided target discovery, precision gene editing, and GMP manufacturing to advance therapeutics for oncology, rare disease, and immunology.
0Pipeline programs
0Phase II trials
0On-target edit rate
Drag to rotate · Hover base pairs
Platform
Four integrated engines.
One discovery loop.
Click a node to see how Helix connects computational design to the clinic.
Pipeline
Therapeutic focus:
Therapeutic focus:
Oncology & rare disease
Mechanism of action
How HelixEdit™
corrects at the source.
Step through the HB-401 pathway — from LNP delivery to durable protein correction. Built for clinicians, patients, and partners who need clarity, not marketing.
Clinical trials
Find a study.
Check eligibility.
Filter active Helix Bio trials by condition, phase, or recruitment status. Each listing links to full protocol details and site contacts.
Company timeline
Built for the long arc
of therapeutic impact.
What we do
At Helix Bio, we advance bold research at the intersection of synthetic biology, machine learning, and clinical medicine — building programmable therapeutics that target the root cause of disease, not just its symptoms.
Move cursor over text to reveal · 0% decoded
Image 01
GMP manufacturing suite
- Editing platform
- HelixEdit™ · CRISPR + base editing
- Delivery
- LNP & AAV vectors · tissue-specific
- Manufacturing
- 50L–500L single-use bioreactors
- Quality
- ISO 13485 · FDA pre-IND ready
Insights
Research & perspectives.
Clinical
Phase II interim: HB-401 in ATTR amyloidosis
View story ↗Manufacturing
Scaling AAV from bench to 500L
View story ↗Resource library
Documents for partners,
investors & patients.
Download fact sheets, pipeline snapshots, publications, and regulatory letters. Updated quarterly.
Careers
Join the team building
programmable medicine.
6 open roles across R&D, manufacturing, clinical, and operations.
Partner with us
Let's build the next
therapeutic breakthrough.
Research collaborations, platform licensing, and co-development inquiries welcome.